公开(公告)号：WO2017049411A1

公开(公告)日：2017-03-30

申请号：PCT/CA2016/051122

申请日：2016-09-23

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： MONNIER, Philippe Patrick ,  TASSEW, Nardos G. ,  BAGLAENKO, Yuriy

IPC: A61K38/17 ,  A61K39/395 ,  A61K49/00 ,  A61P21/00 ,  A61P25/28 ,  C07K14/47

CPC classification number: A61K38/179 ,  A61K38/1709 ,  A61K39/395 ,  C07K14/47

Abstract: Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as methods and compositions for promoting re-myelination and preventing de-myelination. Compositions include RGMa, soluble RGMa, and functional fragments and variants thereof, RGMc, soluble RGMc, and functional fragments and variants thereof, and Neogenin peptides including 4Ig.

Abstract translation: 本文公开了用于增加和减少用于治疗疾病和病症的血脑屏障的渗透性并促进药物递送至脑的方法和组合物，以及用于促进再髓鞘化和预防脱发的方法和组合物， 髓鞘形成。 组合物包括RGMa，可溶性RGMa及其功能片段及其变体，RGMc，可溶性RGMc及其功能片段及变体，以及包含4Ig的Neogenin肽。

公开(公告)号：WO2015039212A1

公开(公告)日：2015-03-26

申请号：PCT/CA2014/000614

申请日：2014-08-06

Applicant: UNIVERSITY HEALTH NETWORK (UHN): TECHNOLOGY DEVELOPMENT AND COMMERCIALIZATION

Inventor： MONNIER, Philippe P. ,  TASSEW, Nardos G.

IPC: C07K14/705 ,  A61K31/137 ,  A61K38/17 ,  A61K39/395 ,  A61P25/00 ,  A61P9/10 ,  C07K14/435 ,  G01N33/53

CPC classification number: A61K38/443 ,  A61K31/137 ,  A61K31/365 ,  A61K31/495 ,  A61K31/7048 ,  A61K31/724 ,  A61K38/177 ,  A61K38/482 ,  A61K2039/505 ,  C07K14/435 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C12Y101/03006 ,  G01N33/5058 ,  G01N33/53 ,  G01N2333/4703

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

Abstract translation: 本文公开了调节排斥导向分子A（RGMa）和新生物或脂质筏之间的顺式相互作用的试剂。 试剂的调节可能包括阻断RGMa和Neogenin之间的顺式相互作用和/或破坏脂筏。 反过来，这促进神经元细胞存活和轴突生长和/或再生。 本文还公开了治疗有需要的受试者的疾病的方法。 该方法可以包括向受试者施用该药剂。 本文进一步公开的是鉴定调节RGMa和Neogenin之间的顺式相互作用的试剂的方法。

公开(公告)号：WO2013113107A1

公开(公告)日：2013-08-08

申请号：PCT/CA2013/000104

申请日：2013-02-04

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： MONNIER, Philippe Patrick ,  TASSEW, Nardos G.

IPC: C07K14/705 ,  A61K38/07 ,  A61K38/08 ,  A61K38/17 ,  A61K39/395 ,  A61P25/00 ,  C07K14/47 ,  C07K16/18 ,  C07K16/28 ,  C07K17/00

CPC classification number: C07K14/4703 ,  A61K38/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28

Abstract: Methods of stimulating neuron survival, axon growth and/or promoting axon regeneration of a neogenin expressing cell in a subject in need thereof are provided. The methods involve for example, administering to a subject in need thereof a PPC inhibitor, optionally a SKI-1 inhibitor and/or a furin inhibitor. Cleaved RGMa inhibits neogenin mediated axon growth. The SKI-1 inhibitor and/or furin inhibitor inhibit cleavage of RGMa, thereby stimulating neuron survival, axon growth and/or promoting axon regeneration.

Abstract translation: 提供了在有需要的受试者中刺激神经元存活，轴突生长和/或促进表达新生细胞的细胞的轴突再生的方法。 所述方法包括例如向有需要的受试者施用PPC抑制剂，任选的SKI-1抑制剂和/或弗林蛋白酶抑制剂。 切割的RGMa抑制新生物介导的轴突生长。 SKI-1抑制剂和/或弗林蛋白酶抑制剂抑制RGMa的切割，从而刺激神经元存活，轴突生长和/或促进轴突再生。

公开(公告)号：EP3352778A1

公开(公告)日：2018-08-01

申请号：EP16847698.4

申请日：2016-09-23

Applicant: University Health Network

Inventor： MONNIER, Philippe Patrick ,  TASSEW, Nardos G. ,  BAGLAENKO, Yuriy

IPC: A61K38/17 ,  A61K39/395 ,  A61K49/00 ,  A61P21/00 ,  A61P25/28 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A61K38/179 ,  A61K39/395 ,  A61K49/00 ,  A61P21/00 ,  A61P25/14 ,  A61P25/28 ,  C07K14/47

Abstract: Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as methods and compositions for promoting re-myelination and preventing de-myelination. Compositions include RGMa, soluble RGMa, and functional fragments and variants thereof, RGMc, soluble RGMc, and functional fragments and variants thereof, and Neogenin peptides including 4Ig.

公开(公告)号：EP3046935A1

公开(公告)日：2016-07-27

申请号：EP14846230.2

申请日：2014-08-06

Applicant: University Health Network (UHN): Technology Development And Commercialization

Inventor： MONNIER, Philippe P. ,  TASSEW, Nardos G.

IPC: C07K14/705 ,  A61K31/137 ,  A61K38/17 ,  A61K39/395 ,  A61P25/00 ,  A61P9/10 ,  C07K14/435 ,  G01N33/53

CPC classification number: A61K38/443 ,  A61K31/137 ,  A61K31/365 ,  A61K31/495 ,  A61K31/7048 ,  A61K31/724 ,  A61K38/177 ,  A61K38/482 ,  A61K2039/505 ,  C07K14/435 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C12Y101/03006 ,  G01N33/5058 ,  G01N33/53 ,  G01N2333/4703

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

Abstract translation: 公开的是传入剂并调节排斥性引导分子A（RGMA）和再生蛋白或脂质筏之间的相互作用的顺式。 调制由代理可以包括阻断顺式和再生蛋白RGMA和/或破坏脂质筏之间的相互作用。 反过来，这也促进神经元细胞存活和轴突生长和/或再生。 所以在游离缺失盘是在需要其的受试者中治疗疾病的方法。 该方法可以包括施用所述试剂给受试者。 在进一步游离缺失盘是识别的试剂做的方法调制的顺式和再生蛋白RGMA之间的相互作用。